Your SlideShare is downloading. ×
0
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

TapImmune, Inc. (OTCBB: TPIV; Stock Twits: $TPIV)

1,137

Published on

TapImmune Inc. (OTCBB: TPIV) is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead …

TapImmune Inc. (OTCBB: TPIV) is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,137
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. 08/01/11 TapImmune Inc OTC BB:TPIV www.tapimmune.com OTCBB: TPIV
  • 2. Cautionary Statement Regarding Forward Looking Statements
    • Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company ’s plan of operations and finances, the potential for the Company’s vaccines and proposed clinical trials.
    • The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.
    08/01/11 TapImmune Inc
  • 3. 08/01/11 TapImmune Inc “ Development of Immunotherapies for cancer & infectious disease ”
  • 4. Market for Immunotherapies/Vaccines
    • Fastest growing segment of pharmaceutical market:
      • Cancer:
        • Projected $6 billion U.S. for cancer vaccines by 2010 with CAGR of 70-100%
        • Stimulated by recent approvals of Dendreon ’s Provenge and BMS Yervoy
      • Infectious Disease:
        • Projected market for 2010 - $11 billion
        • Viral pandemics, societal pathogens, bio-defense
    08/01/11 TapImmune Inc
  • 5. TAP Technology Platform
    • TAP – Transporters associated with antigen presentation
    • Key component in immune recognition pathway
    • Stimulates T-cell recognition of antigens and production of cytotoxic T-cells that can infiltrate tumors
    • Patents confer broad IP protection
    08/01/11 TapImmune Inc
  • 6. TAP is “switched off” in Cancer
    • Many tumors have low or no expression of TAP
    • Tumors not recognized as foreign by immune system
    • Diminished expression of TAP is associated with disease susceptibility, progression and metastasis
    • Vectors re-introducing TAP into tumors boost immunity and reduce tumor burden
    08/01/11 TapImmune Inc
  • 7. Need to Augment TAP levels in Infectious Disease
    • Viral infections produce a range of viral peptides that may “overwhelm” TAP system
    • Insufficient viral antigens presented to the cellular immune system
    • Diminished expression of TAP is associated with disease susceptibility
    • Vectors augmenting normal TAP levels boost immunity and greatly improved vaccine efficacy
    08/01/11 TapImmune Inc
  • 8. Role of TAP (TAP1/TAP2) in loading peptides to MHC Class I molecules and presentation to Cytotoxic T-cells 08/01/11 TapImmune Inc
  • 9. 08/01/11 TapImmune Inc TAP treatment restores Immune Recognition in Cancer Tumor cells now visible to the immune system TAP
  • 10. 08/01/11 TapImmune Inc TAP Enhances Immune Recognition in Infectious Disease Greater number of viral antigens visible to the immune system TAP
  • 11. Efficacy of TAP vector technology
    • Cancer:
      • Mouse models of metastatic melanoma and small cell lung cancer:
        • Reduced metastasis
        • Higher survival
    • Infectious Disease:
      • 100-1000 fold increase in efficacy of smallpox vaccine in animals.
    08/01/11 TapImmune Inc
  • 12. Clinical Development: HER2/neu +ve Breast Cancer Vaccine
    • Combination of TAP + HER2/neu antigens from Mayo Clinic
      • applicable to ~ 80% of HER2/neu +ve patients
      • IND for Phase I studies approved
    • Current therapy:
      • Trastuzumab (Herceptin) over $5billion in annual sales
      • applicable to ~ 30% of HER2/neu +ve patients
    08/01/11 TapImmune Inc
  • 13. Research Smallpox/Biodefense Vaccines
    • TAP improved potency of smallpox vaccine by 100-1000 fold
    • TAP + peptide antigens licensed from Mayo Clinic
      • Broader patient population; cheaper, longer shelf-life
    • “ Animal Efficacy Rule” FDA pathway (24-36 months to potential stockpiling)
    • Potential for TAP to be stockpiled for variety of emerging bio-threats, e.g. Dengue
    08/01/11 TapImmune Inc
  • 14. Leverage of Collaborations
    • Crucell NV
      • TAP manufacturing
    • Research Collaboration with Aeras Global TB Vaccine Foundation
      • TB antigens (Phase II clinical) + TAP
    • License Option Agreements with Mayo Clinic:
      • HER2/neu +ve breast cancer antigen technology
      • Smallpox virus antigen technology
    08/01/11 TapImmune Inc
  • 15. Advisors & R&D Team
      • Mac Cheever (Corixa; Fred Hutchinson Cancer Center)
      • Mark Reddish (Biomira; ID Biomedical)
      • Keith Knutson (Mayo Clinic)
      • Greg Poland (Mayo Clinic)
      • Lynn Depippo (Sherbrook Capital Management)
    08/01/11 TapImmune Inc
  • 16. 08/01/11 TapImmune Inc
    • Technology discovery at University of British Columbia
    • Founded as a public corporation on OTCBB (TPIV)
    • Based in Seattle, WA
    • ~ 47 million shares outstanding (22 million in float)
    • Management & Affiliates ~ 30%
    Corporate Profile www.tapimmune.com
  • 17. Our Vision for TAP
    • Leading immunotherapy in the fight against cancer:
      • Multiple metastatic cancers
      • Multiple combination products
      • Early stage prophylactic use
    • Stockpiled for biodefense threats and viral pandemics:
      • Variety of infectious diseases
      • Emerging bio-terrorist threats
      • Making other vaccines more effective
    08/01/11 TapImmune Inc
  • 18. Looking for Investors that Share our Vision Why Invest in TPIV now?
    • Breakthrough technology
    • Strong product pipeline
    • World-class team and collaborators
    • Risk diversification – cancer & infectious disease
    • Compelling preclinical data
    • Start of clinical programs
    • Undervalued and poised for significant growth
    08/01/11 TapImmune Inc

×